Asthma management is changing, and the preferred option (track 1) recommended by the Global Initiative for Asthma (GINA) is that all people with asthma should be prescribed an inhaled corticosteroid either as needed in mild asthma or regularly for those with more severe asthma.
1 Short acting β
2-agonist bronchodilators (SABAs) certainly have an essential role in the management of acute asthma attacks, but their regular use in the chronic management of asthma has recently been highlighted as having potentially dangerous adverse clinical effects, especially when used without inhaled corticosteroids.
1,2 The association between excess prescriptions of SABAs and increased asthma attacks, healthcare utilisation, and deaths has been known for decades,
3,4 and illustrated so clearly in the SABINA studies
5,6 and the UK National Review of Asthma Deaths (NRAD).
7 Furthermore, it is 30 years since Suissa
et al3,4 demonstrated the association between asthma death and one or more SABA inhaler prescriptions a month with a concomitant reduction in mortality when inhaled corticosteroids (ICS) were used.